Clinical trial
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study
NCT00515216 is registered in ClinicalTrials.gov with Vanderbilt University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study
- Lead sponsor
- Vanderbilt University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2007
- Completion date
- November 30, 2013
- Enrollment
- 26 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.